search

Active clinical trials for "Neoplasms"

Results 4421-4430 of 64586

SBRT for Oligo-residual and Oligoprogressive NSCLC After Treatment With PD-1 Immune Checkpoint Inhibitors...

NSCLC Stage IV

Despite the impressive response rate to PD-1 immune checkpoint inhibitors, resistance inevitably develops in most patients. Stereotactic body radiation therapy (SBRT) plays a growing role in the management of oligometastatic disease. This study aims to evaluate the efficacy and safety of SBRT for oligo-residual or oligoprogressive NSCLC after treatment with PD-1 inhibitors.

Recruiting32 enrollment criteria

Comparison of LLETZ Versus LEEP for the Treatment of Cervical Dysplasia

Cervical Dysplasia

Cervical dysplasia is the precursor of cervical cancer. LEEP and LLETZ are standard surgical procedures to treat cervical dysplasia. There is no direct head-to-head comparison between LEEP and LLETZ in the literature regarding oncologic safety, for which complete resection of the dysplastic lesion (so-called 'in-sano resection') is the most appropriate postoperative surrogate parameter. Further clinical studies are therefore useful to optimize surgical therapy for cervical dysplasia. The primary objective of the present study is to compare LLETZ (resection of the dysplastic lesion including the transformation zone) with targeted resection of the colposcopically conspicuous lesion only (LEEP) and to compare it with regard to oncological safety (defined as non-in-sano rate).

Recruiting8 enrollment criteria

A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade...

Low-grade GliomaAdvanced Solid Tumor

FIREFLY-1 is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of oral pan-RAF inhibitor DAY101 in pediatric, adolescent, and young adult patients with recurrent or progressive low-grade glioma or an advanced solid tumor harboring a known BRAF alteration.

Recruiting10 enrollment criteria

Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT

Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia2 more

This study investigates the infusion safety and potential curative properties of ex-vivo expanded γδ T cells obtained from the same donor for patients who have hematological malignancies and have accepted allogeneic hematopoietic stem cell transplantation.

Recruiting21 enrollment criteria

Tamoxifen Versus Etoposide After First Recurrence in GBM Patients

Glioblastoma Multiforme

The investigator propose a single-center randomized phase II controlled study designed to compare the management of first recurrence of GBM using etoposide versus tamoxifen.

Recruiting23 enrollment criteria

Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma

Glioblastoma

The primary protocol objective is to assess the impact of substituting pulsed reduced dose radiotherapy (pRDR) for standard radiation therapy in the upfront treatment of glioblastoma (GBM) on disease progression.

Recruiting37 enrollment criteria

Glioblastoma Radiotherapy Using IMRT or Proton Beams

Glioblastoma

Radiation therapy is an integral part of the multimodal primary therapy of glioblastomas. As the overall prognosis in this tumor entity remains unfavorable, current research is focused on additional drug therapies, which are often accompanied by increases in toxicity. By using proton beams instead of photon beams, it is possible to protect large parts of the brain which are not affected by the tumor more effectively. An initial retrospective matched-pair analysis showed that this theoretical physical benefit is also clinically associated with a reduction in toxicity during therapy and in the first few months thereafter. The aim of the GRIPS study is to prospectively test this clinical benefit in a randomized, open-label Phase III study. Patients are treated in the study using either modern photon radiation techniques (standard arm) or proton beams (experimental arm). The primary endpoint is the cumulative toxicity CTC grade 2 and higher in the first 4 months. Secondary endpoints include overall survival, progression-free survival, quality of life, and neurocognition.

Recruiting11 enrollment criteria

Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer...

Ovarian Cancer

This study was designed to assess the safety and efficacy of neoadjuvant therapy with mitomycin C plus cisplatin (MP) in BRCA1-mutated ovarian cancer versus standard regimen (paclitaxel plus carboplatin (TP)).

Recruiting7 enrollment criteria

Total Neoadjuvant Therapy in Rectal Cancer Treatment

Rectal Cancer

This is a randomized, controlled, parallel study to determine the efficiency and safety of total neoadjuvant therapy in rectal cancer treatment.

Recruiting8 enrollment criteria

A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients...

Locally Advanced Non-Small Cell Lung Cancer

This is a phase II, open-Label, multi-centre study to determine the efficacy and safety of Camrelizumab plus apatinib in participants with unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), who have not progressed following platinum-based concurrent chemoradiation therapy (cCRT) or sequential chemoradiation therapy (sCRT). This study will be conducted in China mainland.

Recruiting37 enrollment criteria
1...442443444...6459

Need Help? Contact our team!


We'll reach out to this number within 24 hrs